The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043Expands Erasca’s ...

The effective targeting of RAS-mutant acute myeloid leukemia (AML) still remains a challenge; RAS mutations are tied to relapse to targeted therapy, such as resistance to FLT3 inhibitors due to the ...

Erasca, Inc. announced significant progress in its RAS-targeting franchise, including the FDA's clearance of an investigational new drug application for ERAS-0015 and the submission of an IND ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...

Company plans to continue rapidly advancing clinical development program for VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in several advanced KRAS G12D ...

Patients with NSCLC who underwent RT for spine metastasis and tumor genetic profiling were ascertained. Associations between driver gene mutations incidence of local failure were analyzed, followed by ...

Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (ERAS), a clinical-stage precision oncology ...

Pancreatic ductal adenocarcinoma (PDAC) is characterized clinically by poor survival and mechanistically by KRAS- and autophagy-dependent growth. We and others previously demonstrated that inhibition ...

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, ...

Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease Targeted inhibition using small molecule inhibitors works in smoking-related lung cancer. Responses with ...